 chemotherapi dose intens respons median surviv median progression-fre surviv metastat neuroblastoma efficaci commonli drug teniposid cisplatin cddp cyclophosphamid cpm doxo vincristin vcr retrospect analysi clinic trial induct chemotherapi stage IV neuroblastoma patient year age dose intens DI drug milligram squar meter week linear regress analys dl cddp influenc clinic outcom ie proport major respons median surviv median progression-fre surviv pf cpm doxo signific vcr influenc clinic end point mani protocol treatment year none end point durat therapi twenty-on week adequ superior respons median surviv median pf result maxim dose intensif select drug short durat outcom patient poor-risk neuroblastoma